Key facts
- Neutrolis’s last known valuation is $76.6M (Jul 2025).
- It has raised $48.0M across 3 recorded rounds; the latest was Seed Round ($3.5M) in Jun 2025.
- Notable investors include Morningside Group, Oceanpine Capital, First Rice Capital, LabCentral, PBJ Capital — 7 tracked in total.
- Neutrolis has filed 3 Form Ds with the SEC since 2021, most recently Jul 2025 ($3.5M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Neutrolis
Funding rounds
3 roundsAbout Neutrolis
Operator of a biotechnology company intended to develop therapeutics that target neutrophils, the most abundant immune cell in our body. The company utilizes its proprietary platform to power the creation of natural and engineered enzyme analogs that are capable of treating several acute and chronic unmet medical needs and that are optimized for use in therapy, enabling doctors to degrade NETs' biologically inactive fragments to attenuate a severe immune response.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2017
- Employees
- 9
- Website
- neutrolis.com/
- Ownership
- Privately Held (backing)
Neutrolis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neutrolis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neutrolis in its N-PORT filings yet. We sweep new filings monthly.